Comparison 1. Alpha blocker versus placebo or control.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Ability to void spontaneously after TWOC without the need for re‐catheterisation	9	1094	Risk Ratio (M‐H, Fixed, 95% CI)	1.55 [1.36, 1.76]
1.1 Alfuzosin versus control	5	667	Risk Ratio (M‐H, Fixed, 95% CI)	1.40 [1.19, 1.64]
1.2 Tamsulosin versus control	3	321	Risk Ratio (M‐H, Fixed, 95% CI)	1.97 [1.49, 2.59]
1.3 Doxazosin versus control	1	46	Risk Ratio (M‐H, Fixed, 95% CI)	1.09 [0.66, 1.81]
1.4 Silodosin versus control	1	60	Risk Ratio (M‐H, Fixed, 95% CI)	2.09 [1.26, 3.48]
2 Incidence of recurrent urinary retention	8	1023	Risk Ratio (M‐H, Fixed, 95% CI)	0.69 [0.60, 0.79]
2.1 Alfuzosin versus control	5	667	Risk Ratio (M‐H, Fixed, 95% CI)	0.72 [0.60, 0.85]
2.2 Tamsulosin versus control	2	249	Risk Ratio (M‐H, Fixed, 95% CI)	0.66 [0.50, 0.87]
2.3 Doxazosin versus control	1	47	Risk Ratio (M‐H, Fixed, 95% CI)	0.98 [0.65, 1.48]
2.4 Silodosin versus control	1	60	Risk Ratio (M‐H, Fixed, 95% CI)	0.37 [0.18, 0.74]
3 Number with adverse effects due to alpha‐blocker treatment	5	1064	Risk Ratio (M‐H, Fixed, 95% CI)	1.19 [0.75, 1.89]
3.1 Alfuzosin versus control	3	868	Risk Ratio (M‐H, Fixed, 95% CI)	0.91 [0.53, 1.54]
3.2 Tamsulosin versus control	1	149	Risk Ratio (M‐H, Fixed, 95% CI)	2.71 [0.90, 8.14]
3.3 Doxazosin versus control	1	47	Risk Ratio (M‐H, Fixed, 95% CI)	3.13 [0.13, 73.01]
4 Number with serious adverse effects due to alpha‐blocker treatment	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4.1 Alfuzosin versus control	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
5 Number of drop‐outs due to adverse effects of alpha blockers treatment	5	705	Risk Ratio (M‐H, Fixed, 95% CI)	3.94 [1.28, 12.12]
5.1 Alfuzosin versus control	3	509	Risk Ratio (M‐H, Fixed, 95% CI)	2.83 [0.62, 12.93]
5.2 Tamsulosin versus control	1	149	Risk Ratio (M‐H, Fixed, 95% CI)	6.91 [0.87, 54.76]
5.3 Doxazosin versus control	1	47	Risk Ratio (M‐H, Fixed, 95% CI)	3.13 [0.13, 73.01]